The ARPA-H Resilient Extended Automatic Cell Therapies (REACT) program seeks to automatically deliver treatments and monitor for disease from within an individual’s body using bioelectronic devices. 

Funding for awardees varies in amount and is contingent upon the recipient meeting aggressive milestones specific to their project.

The REACT performers are:

• The Mayo Clinic, focusing on the Living Pharmacy track, which will use engineered cells stored in a bioelectronic device to treat Inflammatory Bowel Disease (IBD). Their Engage Assess Secrete (EASE) device will release antibodies to address inflammation and alleviate the current treatment burden of drugs administered every 2-8 weeks. 
• A team from Carnegie Mellon University, focusing on the Living Pharmacy track, which will address obesity and diabetes through its RX On-site Generation Using Electronics (ROGUE), which will precisely stimulate cells within a device to produce drugs to decrease a person’s appetite and cause weight loss while eliminating the need for periodic injections. 
• A team from Columbia University, focusing on the Living Pharmacy track, which will address obesity and diabetes by developing the Bioelectronics for the Delivery of Synthetic Therapeutic with Wireless Control (BIOSYNC) device. They will explore a complementary approach to produce drugs that regulate appetite, digestion, and blood sugar.  
• Another team from Carnegie Mellon University, focusing on both the Living Sentinel and the Living Pharmacy tracks, which will monitor and treat hypothyroidism through their Biointegrated Implantable Systems for Cell-based Sensing and Therapy (BIO-INSYNC) device. BIO-INSYNC will continuously measure a person’s hormone levels and produce precise doses of a missing hormone to maintain proper levels, reducing the burden for people who require life-long daily treatments.